LifeTech Scientific Corporation
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac P… Read more
LifeTech Scientific Corporation (LFTSF) - Net Assets
Latest net assets as of June 2025: $3.74 Billion USD
Based on the latest financial reports, LifeTech Scientific Corporation (LFTSF) has net assets worth $3.74 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.33 Billion) and total liabilities ($1.60 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.74 Billion |
| % of Total Assets | 70.06% |
| Annual Growth Rate | 65.21% |
| 5-Year Change | 47.36% |
| 10-Year Change | 1827.86% |
| Growth Volatility | 2207.73 |
LifeTech Scientific Corporation - Net Assets Trend (2010–2024)
This chart illustrates how LifeTech Scientific Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LifeTech Scientific Corporation (2010–2024)
The table below shows the annual net assets of LifeTech Scientific Corporation from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.48 Billion | +4.56% |
| 2023-12-31 | $3.32 Billion | +13.79% |
| 2022-12-31 | $2.92 Billion | +15.45% |
| 2021-12-31 | $2.53 Billion | +7.28% |
| 2020-12-31 | $2.36 Billion | +103.03% |
| 2019-12-31 | $1.16 Billion | -6.61% |
| 2018-12-31 | $1.24 Billion | +17.80% |
| 2017-12-31 | $1.06 Billion | +21.29% |
| 2016-12-31 | $870.60 Million | +382.93% |
| 2015-12-31 | $180.27 Million | +15.33% |
| 2014-12-31 | $156.31 Million | -33.78% |
| 2013-12-31 | $236.05 Million | -21.53% |
| 2012-12-31 | $300.81 Million | +12.31% |
| 2011-12-31 | $267.84 Million | +8604.58% |
| 2010-12-31 | $3.08 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LifeTech Scientific Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 187463100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.87 Billion | 53.65% |
| Common Stock | $37.00K | 0.00% |
| Other Components | $1.62 Billion | 46.35% |
| Total Equity | $3.49 Billion | 100.00% |
LifeTech Scientific Corporation Competitors by Market Cap
The table below lists competitors of LifeTech Scientific Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CARGOJET INC. VAR VTG
F:CJ8A
|
$838.16 Million |
|
NCR Corp.
LSE:0K45
|
$838.30 Million |
|
Protector Forsikring ASA
OTCGREY:PSKRF
|
$838.66 Million |
|
Mani, Inc.
PINK:MNICF
|
$838.72 Million |
|
Cartrade Tech Limited
NSE:CARTRADE
|
$837.99 Million |
|
Cloetta AB (publ)
ST:CLA-B
|
$837.82 Million |
|
Aguas Andinas S.A
SN:AGUAS-A
|
$837.56 Million |
|
Northking Information Technology Co
SHE:002987
|
$837.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LifeTech Scientific Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,370,242,000 to 3,494,507,000, a change of 124,265,000 (3.7%).
- Net income of 222,388,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 24,937,000.
- Other factors increased equity by 72,945,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $222.39 Million | +6.36% |
| Other Comprehensive Income | $-24.94 Million | -0.71% |
| Other Changes | $72.94 Million | +2.09% |
| Total Change | $- | 3.69% |
Book Value vs Market Value Analysis
This analysis compares LifeTech Scientific Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.29x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $0.00 | $0.23 | x |
| 2011-12-31 | $0.08 | $0.23 | x |
| 2012-12-31 | $0.07 | $0.23 | x |
| 2013-12-31 | $0.06 | $0.23 | x |
| 2014-12-31 | $0.04 | $0.23 | x |
| 2015-12-31 | $0.05 | $0.23 | x |
| 2016-12-31 | $0.22 | $0.23 | x |
| 2017-12-31 | $0.24 | $0.23 | x |
| 2018-12-31 | $0.28 | $0.23 | x |
| 2019-12-31 | $0.28 | $0.23 | x |
| 2020-12-31 | $0.53 | $0.23 | x |
| 2021-12-31 | $0.55 | $0.23 | x |
| 2022-12-31 | $0.66 | $0.23 | x |
| 2023-12-31 | $0.76 | $0.23 | x |
| 2024-12-31 | $0.80 | $0.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LifeTech Scientific Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.36%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.06%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.40x
- Recent ROE (6.36%) is above the historical average (2.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | 3.76% | 0.66x | 0.00x | $3.96 Million |
| 2011 | 4.48% | 8.43% | 0.45x | 1.19x | $-14.58 Million |
| 2012 | 10.91% | 17.83% | 0.50x | 1.23x | $2.70 Million |
| 2013 | -28.36% | -28.42% | 0.44x | 2.25x | $-88.82 Million |
| 2014 | -53.71% | -28.74% | 0.50x | 3.74x | $-96.37 Million |
| 2015 | 1.31% | 0.76% | 0.39x | 4.45x | $-15.67 Million |
| 2016 | 16.79% | 41.28% | 0.27x | 1.53x | $58.89 Million |
| 2017 | 15.53% | 39.96% | 0.32x | 1.21x | $58.19 Million |
| 2018 | 9.76% | 21.75% | 0.36x | 1.23x | $-2.96 Million |
| 2019 | 11.22% | 19.32% | 0.38x | 1.54x | $14.00 Million |
| 2020 | 9.23% | 33.64% | 0.22x | 1.26x | $-17.93 Million |
| 2021 | 11.68% | 31.61% | 0.29x | 1.27x | $42.11 Million |
| 2022 | 11.22% | 29.65% | 0.30x | 1.27x | $35.29 Million |
| 2023 | 7.81% | 20.77% | 0.27x | 1.39x | $-73.78 Million |
| 2024 | 6.36% | 17.06% | 0.27x | 1.40x | $-127.06 Million |
Industry Comparison
This section compares LifeTech Scientific Corporation's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LifeTech Scientific Corporation (LFTSF) | $3.74 Billion | 0.00% | 0.43x | $838.16 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |